Unknown

Dataset Information

0

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

ABSTRACT:

SUBMITTER: Sklavenitis-Pistofidis R 

PROVIDER: S-EPMC6293872 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia.
| S-EPMC7484977 | biostudies-literature
Unknown The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
| S-EPMC2234792 | biostudies-literature
Unknown Onsets of progression and second treatment determine survival of patients with symptomatic Waldenstrom macroglobulinemia.
| S-EPMC6258926 | biostudies-literature
Unknown Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia.
| S-EPMC8137404 | biostudies-literature
Unknown Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
| S-EPMC2727288 | biostudies-literature
Unknown CXCR4-targeted PET imaging using <sup>64</sup>Cu-AMD3100 for detection of Waldenstrom Macroglobulinemia.
| S-EPMC7012167 | biostudies-literature
Unknown Waldenstrom macroglobulinemia treatment algorithm 2018.
| S-EPMC5928091 | biostudies-literature
Unknown Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies.
| S-EPMC7351339 | biostudies-literature
Unknown Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
| S-EPMC5709107 | biostudies-literature
Unknown Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
| S-EPMC2343604 | biostudies-literature